Skip to main content

Advertisement

Table 2 Ongoing clinical trials of rociletinib (CO-1686)

From: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Phase Study population NCT no.
Phase I/II EGFR mutated advanced NSCLC 02580708
Phase I/II EGFR mutated advanced NSCLC 02630186
Phase II/III (TIGER-1) Untreated EGFR mutated advanced NSCLC 02186301
Phase II (TIGER-2) EGFR mutated NSCLC 02147990
Phase III (TIGER-3) EGFR mutated advanced NSCLC after failure of ≥1 previous EGFR TKI and platinum-doublet chemotherapy 02322281
  1. EGFR: epidermal growth factor receptor, NSCLC: non-small cell lung cancer, TKI: tyrosine kinase inhibitor